Overview

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Status:
Not yet recruiting

Trial end date:
2028-05-22

Target enrollment:

Participant gender:

Summary

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are MK-3475A subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pembrolizumab
Pemetrexed